Aktuellt
SENASTE
Redeye embraces the reported data from OssDsign’s TOP FUSION clinical study, and we await further peer-reviewed publication in the intended journal. We anticipate a continuous positive share price development on the back of the news and ahead of the Q4 2023 report in mid-February. We reiterate our SEK15 base case, representing a c60% upside, which we believe should close during the year.
LÄS MER
